The use of meloxicam oral suspension to treat musculoskeletal lameness in cattle
Authors:
Open Access
- 1 November 2016
- journal article
- research article
- Published by Taylor & Francis in Veterinary Medicine: Research and Reports
- Vol. ume 7, 149-155
Abstract
The use of meloxicam oral suspension to treat musculoskeletal lameness in cattle D Nagel,1 R Wieringa,2 J Ireland,3 Merle E Olson1 1Solvet/Alberta Veterinary Laboratories, Calgary, AB, 2Heartland Veterinary Services, Listowel, 3Albadon Farm Ltd, Teeswater, ON, Canada Lameness in beef and dairy cattle is responsible for economic losses and has significant animal welfare implications. It has been proposed that early treatment with analgesics not only reduces acute pain but also leads to reduced long-term sensitization. Fifty-three cattle (309–954 kg body weight [BW], mean: 656 kg) with musculoskeletal lameness were scored for lameness and inflammation, then randomly assigned to a single oral treatment with meloxicam oral suspension (MOS) (28 animals) at 1 mg/kg or saline at 1 mL/15 kg BW. Lameness and inflammation were reevaluated 3 days after treatment, and 26 of 28 (92.8%) MOS-treated animals had a reduced lameness score, while only three of 25 control animals had a reduced lameness score. MOS was effective in treating musculoskeletal disease in cattle. In an accompanying residue depletion study, 22 lactating Holstein cows (BW: 553–927 kg, mean: 713 kg) were used in the study. All 22 animals received MOS at the dose of 1 mg/kg BW once. Milk (500 mL sample from the full milking volume) was collected at approximately 48, 72, 96, and 120 hours after the treatment. Samples were subjected to in vitro analysis for quantification of meloxicam by liquid chromatography and mass spectroscopy. The mean meloxicam concentration at 48 and 72 hours were 30.75 and 2.82 ng/mL, respectively. The meloxicam milk concentration was below the limit of quantification (1 ng/mL) in 15 of 22 animals at 96 hours and in 22 of 22 animals at 120 hours. The milk meloxicam levels in all animals were below the maximum residue limit (Canada: 35 ng/mL; Europe: 15 ng/mL) at the 72-hour sampling. Keywords: meloxicam, lameness, musculoskeletal, residue, milk, cattleKeywords
This publication has 12 references indexed in Scilit:
- Efficacy of oral meloxicam suspension for prevention of pain and inflammation following band and surgical castration in calvesBMC Veterinary Research, 2016
- Clinical Pharmacology of Analgesic Drugs in CattleVeterinary Clinics of North America: Food Animal Practice, 2015
- Administration of a NSAID (meloxicam) affects lying behaviour after caesarean section in beef cowsApplied Animal Behaviour Science, 2014
- Impact of oral meloxicam administered alone or in combination with gabapentin on experimentally induced lameness in beef calves1Journal of Animal Science, 2014
- Assessment and Management of Pain Associated with Lameness in CattleVeterinary Clinics of North America: Food Animal Practice, 2013
- Postoperative analgesic efficacy of meloxicam in lame dairy cows undergoing resection of the distal interphalangeal jointJournal of Dairy Science, 2013
- Pharmacokinetics and milk secretion of gabapentin and meloxicam co‐administered orally in Holstein‐Friesian cowsJournal of Veterinary Pharmacology and Therapeutics, 2012
- Assessment of the duration of the pain response associated with lameness in dairy cows, and the influence of treatmentNew Zealand Veterinary Journal, 2008
- Analgesics Improve the Gait of Lame Dairy CattleJournal of Dairy Science, 2008
- A lameness scoring system that uses posture and gait to predict dairy cattle reproductive performanceTheriogenology, 1997